Online citations, reference lists, and bibliographies.
← Back to Search

A Sensitive Procedure For The Quantitation Of Free And N-(2-hydroxypropyl) Methacrylamide Polymer-bound Doxorubicin (PK1) And Some Of Its Metabolites, 13-dihydrodoxorubicin, 13-dihydrodoxorubicinone And Doxorubicinone, In Human Plasma And Urine By Reversed-phase HPLC With Fluorimetric Detection.

D. Fraier, E. Frigerio, E. Pianezzola, M. Strolin Benedetti, J. Cassidy, P. Vasey
Published 1995 · Chemistry, Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
A high-performance liquid chromatographic assay has been developed and validated for the determination in plasma and urine of doxorubicin (DXR) and some of its metabolites released in vivo from an N-(2-hydroxypropyl)methacrylamide (HPMA) polymer containing DXR linked through its aminosugar moiety to the polymer via an oligopeptide spacer (PK1). The method also allows measurement of the DXR still bound to the polymer. Following addition of two internal standards, the free compounds were extracted twice with isopropanol-chloroform (25:75, v/v). The first extraction was performed at physiological pH and the second after buffering at pH 8.4, in order to extract the aglycones and the glycosides, respectively. Determination of total DXR (polymer-bound plus free DXR) was performed, after quantitative acid hydrolysis to release doxorubicinone from free or polymer-bound DXR, by extraction with the same solvent mixture at pH 7.4. In both cases the organic phase was evaporated to dryness; the compounds were then separated by reversed-phase high-performance liquid chromatography (HPLC) under isocratic conditions and quantitated by fluorimetric detection. In the chromatograms all the analytes appeared to be separated at the baseline and no interference from blank human plasma and urine was observed. The suitability of the method for in vivo samples was checked by the analysis of plasma and urine samples obtained from a cancer patient who had received a single intravenous dose of the test compound.
This paper references
10.1056/NEJM198107163050305
The anthracycline antineoplastic drugs.
R. C. Young (1981)
Preclinical trials with combinations and conjugates of T101 monoclonal antibody and doxorubicin.
R. Dillman (1986)
Doxorubicin (adriamycin) cardiomyopathy.
E. Saltiel (1983)
10.1016/0168-3659(92)90088-9
Preclinical evaluation of polymer-bound doxorubicin
R. Duncan (1992)
10.1016/0006-2952(89)90688-6
Comparative activity of anthracycline 13-dihydrometabolites against rat glioblastoma cells in culture.
B. Schott (1989)
10.1016/0168-3659(89)90017-5
Anticancer agents coupled to N-(2-hydroxypropyl)methacrylamide copolymers. 3. Evaluation of adriamycin conjugates against mouse leukaemia L1210 in vivo
R. Duncan (1989)
10.1016/0006-2952(90)90293-T
The pharmacokinetics of polymer-bound adriamycin.
L. Seymour (1990)
10.7326/0003-4819-91-5-710
Risk factors for doxorubicin-induced congestive heart failure.
D. V. Von Hoff (1979)
10.1007/BF00255281
Antitumor and toxicity evaluation of free doxorubicin and doxorubicin entrapped in cardiolipin liposomes
A. Rahman (2004)
10.1002/BDD.2510060111
Adriamycin-loaded albumin microspheres: preparation, in vivo distribution and release in the rat.
N. Willmott (1985)
10.1016/0168-3659(89)90018-7
Poly(carboxylic acid) polymers as carriers for anthracyclines
F. Zunino (1989)
10.1016/0168-3659(85)90006-9
The synthesis and characterization of polypeptide-adriamycin conjugates and its complexes with adriamycin. Part I
W. Heeswijk (1985)
10.1089/CDD.1987.4.191
Continuous infusion or intravenous bolus: what is the rationale for doxorubicin administration?
J. Robert (1987)



This paper is referenced by
10.1080/10826079808005850
Utility of Ion-Pair Chromatography for Analysis of Some Anthracyclines in Plasma and Urine
Samy Emara (1998)
10.1016/j.jchromb.2011.07.010
Quantitative liquid chromatographic analysis of anthracyclines in biological fluids.
Kristof E. Maudens (2011)
10.1016/S0378-4347(01)00346-2
Anthracyclines: recent developments in their separation and quantitation.
G. Zagotto (2001)
10.1016/J.JCHROMB.2003.10.067
Validation study of assay method for DE-310, a novel polymer-bound camptothecin derivative, and the free drug in mouse plasma by liquid chromatography with fluorimetric detection.
T. Oguma (2004)
Phase I Clinical and Pharmacokinetic Study of PK1 [N-(2-Hydroxypropyl)methacrylamide Copolymer Doxorubicin]: First Member of a New Class of Chemotherapeutic Agents—Drug-Polymer Conjugates
P. Vasey (1999)
10.1135/CCCC2009081
VOLTAMMETRIC AND AMPEROMETRIC DETERMINATION OF DOXORUBICIN USING CARBON PASTE ELECTRODES
Zuzana Jemelková (2009)
Pharmacokinetics of PK 1 and Doxorubicin in Experimental Colon Tumor Models with Differing Responses to PK 11
P. Loadman (1999)
10.1177/096032719801700204
Preclinical toxicology of a novel polymeric antitumour agent: HPMA copolymerdoxorubicin (PK1)
R. Duncan (1998)
10.1106/QBKY-E3VM-19K4-3GA5
Dextrins as Carriers for Drug Targeting: Reproducible Succinoylation as a Means to Introduce Pendant Groups
D. Hreczuk-Hirst (2001)
10.1002/BMC.409
Validation study of a method for assaying DE-310, a macromolecular carrier conjugate containing an anti-tumor camptothecin derivative, and the free drug in tumor tissue by high performance liquid chromatography/atmospheric pressure chemical ionization tandem mass spectrometry.
T. Oguma (2005)
10.1016/J.JCHROMB.2005.01.005
Validation study of a method for assaying DE-310, a macromolecular carrier conjugate containing an anti-tumor camptothecin derivative, and the free drug in human plasma by HPLC and LC/MS/MS.
T. Oguma (2005)
10.1007/s00280-013-2209-7
Validation of tumour models for use in anticancer nanomedicine evaluation: the EPR effect and cathepsin B-mediated drug release rate
R. Duncan (2013)
10.1016/j.jpba.2018.06.031
Optimization of LC method for the quantification of doxorubicin in plasma and urine samples in view of pharmacokinetic, biomedical and drug monitoring therapy studies
Olga Maliszewska (2018)
10.1016/j.addr.2009.05.007
Development of HPMA copolymer-anticancer conjugates: clinical experience and lessons learnt.
R. Duncan (2009)
10.1016/S0168-3659(98)00124-2
Preliminary clinical study of the distribution of HPMA copolymers bearing doxorubicin and galactosamine.
P. Julyan (1999)
10.1097/CAD.0b013e3283355227
Antitumor activity and toxicological properties of doxorubicin conjugated to &agr;,&bgr;-poly[(2-hydroxyethyl)-L-aspartamide] administered intraperitoneally in mice
Xiaoyun Cheng (2010)
10.1016/j.redox.2019.101311
A precision medicine approach to defining the impact of doxorubicin on the bioenergetic-metabolite interactome in human platelets
M. Smith (2019)
10.1016/J.EJPS.2007.02.004
Biodistribution of doxorubicin-alkylated poly(L-lysine citramide imide) conjugates in an experimental model of peritoneal carcinomatosis after intraperitoneal administration.
Pierre-Emmanuel Colombo (2007)
10.1097/CAD.0b013e3283406e85
Galactosylated &agr;,&bgr;-poly[(2-hydroxyethyl)-L-aspartamide]-bound doxorubicin: improved antitumor activity against hepatocellular carcinoma with reduced hepatotoxicity
Xiaoyun Cheng (2011)
10.1038/sj.bjc.6690657
Population pharmacokinetics in phase I drug development: a phase I study of PK1 in patients with solid tumours
A. Thomson (1999)
10.1016/j.biomaterials.2014.03.046
pH-responsive polymer-liposomes for intracellular drug delivery and tumor extracellular matrix switched-on targeted cancer therapy.
Yi-Ting Chiang (2014)
10.1016/J.JCHROMB.2006.10.073
Traces of phosgene in chloroform: consequences for extraction of anthracyclines.
K. Maudens (2007)
10.1556/1326.2017.00201
Determination of adriamycin content in pectin–adriamycin conjugate in a two-phase reaction system by high-performance liquid chromatography
Maosheng Ran (2018)
10.1016/j.jconrel.2012.06.029
HPMA copolymer-doxorubicin conjugates: The effects of molecular weight and architecture on biodistribution and in vivo activity.
T. Etrych (2012)
10.33549/PHYSIOLRES.933137
The comparison of in vivo properties of water-soluble HPMA-based polymer conjugates with doxorubicin prepared by controlled RAFT or free radical polymerization.
P. Chytil (2015)
10.4067/S0717-97072013000200006
"RAPID AND SIMULTANEOUS DETERMINATION OF ADRIAMYCIN, BLEOMYCIN, VINBLASTINE AND DACARBAZINE IN PLASMA OF HODGKIN'S LYMPHOMA PATIENTS BY A REVERSED PHASE HPLC METHOD"
M. Z. Malik (2013)
10.1016/S0731-7085(99)00315-5
Determination of MAG-camptothecin, a new polymer-bound camptothecin derivative, and free camptothecin in dog plasma by HPLC with fluorimetric detection.
D. Fraier (2000)
Pharmacokinetics of PK1 and doxorubicin in experimental colon tumor models with differing responses to PK1.
P. Loadman (1999)
10.1016/j.ejps.2014.02.016
Polymer conjugates of doxorubicin bound through an amide and hydrazone bond: Impact of the carrier structure onto synergistic action in the treatment of solid tumours.
T. Etrych (2014)
10.1021/mp200394t
Nanomedicine(s) under the microscope.
R. Duncan (2011)
10.33549/PHYSIOLRES.933140
Nanotherapeutics with anthracyclines: methods of determination and quantification of anthracyclines in biological samples.
E. Koziolová (2015)
10.1016/j.ygyno.2011.05.032
Intraperitoneal administration of novel doxorubicin loaded polymeric delivery systems against peritoneal carcinomatosis: experimental study in a murine model of ovarian cancer.
Pierre-Emmanuel Colombo (2011)
See more
Semantic Scholar Logo Some data provided by SemanticScholar